Literature DB >> 9114082

Axillary lymph node metastases: screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET.

L P Adler1, P F Faulhaber, K C Schnur, N L Al-Kasi, R R Shenk.   

Abstract

PURPOSE: To evaluate [fluorine-18]2-deoxy-2-fluoro-D-glucose (FDG) positron emission tomography (PET) of the axilla as a screening test for detecting regional spread of breast cancer.
MATERIALS AND METHODS: High-dose FDG PET of the axilla was successfully performed in 50 patients (age range, 36-79 years) with breast cancer before 52 axillary lymph node dissections. Two additional patients had scans that were uninterpretable because of intense myocardial activity that obscured the axilla.
RESULTS: The sensitivity and negative predictive value were both 95%, the specificity was 66%, and the overall accuracy was 77%. The only false-negative PET scan was obtained in the largest patient, who had a low-quality scan.
CONCLUSION: Patients with negative PET scans had such a low risk for axillary lymph node metastases that axillary dissection was not warranted. Patients with positive PET scans required dissection to confirm the presence and determine the number of positive lymph nodes. Had this algorithm been used to select patients for dissection, approximately $120,000 in charges ($2,300 per patient) would have been saved and 22 patients would have been spared the morbidity of axillary lymph node dissection. Within this study population, PET scans of the axilla were interpreted with sufficient sensitivity for PET to serve as a cost-effective screening test for axillary lymph node metastases.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9114082     DOI: 10.1148/radiology.203.2.9114082

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  15 in total

1.  Semiquantitative analysis of maximum standardized uptake values of regional lymph nodes in inflammatory breast cancer: is there a reliable threshold for differentiating benign from malignant?

Authors:  Selin Carkaci; Beatriz E Adrada; Eric Rohren; Wei Wei; Mohammad A Quraishi; Osama Mawlawi; Thomas A Buchholz; Wei Yang
Journal:  Acad Radiol       Date:  2012-02-01       Impact factor: 3.173

2.  Determinants of diagnostic performance of [F-18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer.

Authors:  Jacobus J M van der Hoeven; Otto S Hoekstra; Emile F I Comans; Rik Pijpers; Robert P A Boom; Dick van Geldere; Sybren Meijer; Adriaan A Lammertsma; Gerrit J J Teule
Journal:  Ann Surg       Date:  2002-11       Impact factor: 12.969

3.  Cost-effectiveness of positron emission tomography in breast cancer.

Authors:  J Scott Sloka; Peter D Hollett; Maria Mathews
Journal:  Mol Imaging Biol       Date:  2005 Sep-Oct       Impact factor: 3.488

4.  Fluorodeoxyglucose positron emission tomography for detection of recurrent or metastatic breast cancer.

Authors:  T S Kim; W K Moon; D S Lee; J K Chung; M C Lee; Y K Youn; S K Oh; K J Choe; D Y Noh
Journal:  World J Surg       Date:  2001-07       Impact factor: 3.352

Review 5.  Machine learning in quantitative PET: A review of attenuation correction and low-count image reconstruction methods.

Authors:  Tonghe Wang; Yang Lei; Yabo Fu; Walter J Curran; Tian Liu; Jonathon A Nye; Xiaofeng Yang
Journal:  Phys Med       Date:  2020-07-29       Impact factor: 2.685

Review 6.  Use of tomographic nuclear medicine procedures, SPECT and pinhole SPECT, with cationic lipophilic radiotracers for the evaluation of axillary lymph node status in breast cancer patients.

Authors:  Giuseppe Madeddu; Angela Spanu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-15       Impact factor: 9.236

7.  Impact of FDG PET on the preoperative staging of newly diagnosed breast cancer.

Authors:  Tevfik F Cermik; Ayse Mavi; Sandip Basu; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-24       Impact factor: 9.236

Review 8.  The role of positron emission tomographic imaging in breast cancer.

Authors:  Michelle D McDonough; Elizabeth R DePeri; Betty A Mincey
Journal:  Curr Oncol Rep       Date:  2004-01       Impact factor: 5.075

9.  Regulation of the Warburg effect in early-passage breast cancer cells.

Authors:  Ian F Robey; Renu M Stephen; Kathy S Brown; Brenda K Baggett; Robert A Gatenby; Robert J Gillies
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

Review 10.  FDG-PET for axillary lymph node staging in primary breast cancer.

Authors:  Flavio Crippa; Alberto Gerali; Alessandra Alessi; Roberto Agresti; Emilio Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-05       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.